Rhythmic Control of the ARF-MDM2 Pathway by ATF4 Underlies Circadian Accumulation of p53 in Malignant Cells

被引:29
|
作者
Horiguchi, Michiko [1 ,2 ]
Koyanagi, Satoru [1 ]
Hamdan, Ahmed M. [1 ]
Kakimoto, Keisuke [1 ]
Matsunaga, Naoya [1 ]
Yamashita, Chikamasa [2 ]
Ohdo, Shigehiro [1 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut, Fukuoka 8128582, Japan
[2] Tokyo Univ Sci, Fac Pharmaceut Sci, Chiba, Japan
基金
日本学术振兴会;
关键词
LARGE T-ANTIGEN; SUPRACHIASMATIC NUCLEUS; DOSING SCHEDULE; FEEDBACK LOOP; IN-VIVO; CLOCK; EXPRESSION; TRANSCRIPTION; GENE; PROTEIN;
D O I
10.1158/0008-5472.CAN-12-2492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The sensitivity of cancer cells to chemotherapeutic agents varies according to circadian time. Most chemotherapeutic agents ultimately cause cell death through cell-intrinsic pathways as an indirect consequence of DNA damage. The p53 tumor suppressor gene (TRP53) configures the cell deaths induced by chemotherapeutic agents. In this study, we show that the transcription factor ATF4, a component of the mammalian circadian clock, functions in circadian accumulation of p53 protein in tumor cells. In murine fibroblast tumor cells, ATF4 induced the circadian expression of p19ARF (Cdkn2a). Oscillation of p19ARF interacted in a time-dependent manner with MDM2, a specific ubiquitin ligase of p53, resulting in a rhythmic prevention of its degradation by MDM2. Consequently, the half-life of p53 protein varied in a circadian time-dependent manner without variation in mRNA levels. The p53 protein accumulated during those times when the p19ARF-MDM2 interaction was facilitated. Notably, the ability of the p53 degradation inhibitor nutlin-3 to kill murine fibroblast tumor cells was enhanced when the drug was administered at those times of day during which p53 had accumulated. Taken together, these results suggested that ATF4-mediated regulation of the p19ARF-MDM2 pathway underlies the circadian accumulation of p53 protein in malignant cells. Furthermore, they suggest an explanation for how the sensitivity of cancer cells to chemotherapeutic agents is enhanced at those times of day when p53 protein has accumulated, as a result of circadian processes controlled by ATF4. Cancer Res; 73(8); 2639-49. (C) 2013 AACR.
引用
收藏
页码:2639 / 2649
页数:11
相关论文
共 50 条
  • [1] Rhythmic regulation of ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 protein in malignant tumor cells
    Horiguchi, Michiko
    Koyanagi, Satoru
    Shiromizu, Shoya
    Sasaki, Hirokazu
    Hamdan, Ahmed
    Matsunaga, Naoya
    Ohdo, Shigehiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 200P - 200P
  • [2] MDM2 AMPLIFICATION, P53 MUTATION, AND P53 ACCUMULATION MALIGNANT FIBROUS HISTIOCYTOMA
    REID, AH
    TSAI, MM
    VENZON, DJ
    WRIGHT, CF
    LACK, EE
    OLEARY, TJ
    LABORATORY INVESTIGATION, 1995, 72 (01) : A11 - A11
  • [3] P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation.
    Tian, Xiaobing
    Ahsan, Nagib
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Control of p53 ubiquitination and nuclear export by MDM2 and ARF
    Zhang, YP
    Xiong, Y
    CELL GROWTH & DIFFERENTIATION, 2001, 12 (04): : 175 - 186
  • [5] MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma
    Reid, AH
    Tsai, MM
    Venzon, DJ
    Wright, CF
    Lack, EE
    OLeary, TJ
    DIAGNOSTIC MOLECULAR PATHOLOGY, 1996, 5 (01) : 65 - 73
  • [6] Inactivation of the ARF–MDM-2–p53 pathway in sporadic Burkitt's lymphoma in children
    M Wilda
    J Bruch
    L Harder
    D Rawer
    A Reiter
    A Borkhardt
    W Woessmann
    Leukemia, 2004, 18 : 584 - 588
  • [7] P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
    Tian, Xiaobing
    Ahsan, Nagib
    Lulla, Amriti
    Lev, Avital
    Abbosh, Philip
    Dicker, David T.
    Zhang, Shengliang
    El-Deiry, Wafik S.
    NEOPLASIA, 2021, 23 (03): : 304 - 325
  • [8] High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
    Carr-Wilkinson, Jane
    O'Toole, Kieran
    Wood, Katrina M.
    Challen, Christine C.
    Baker, Angela G.
    Board, Julian R.
    Evans, Laura
    Cole, Michael
    Cheung, Nai-Kong V.
    Boos, Joachim
    Koehler, Gabriele
    Leuschner, Ivo
    Pearson, Andrew D. J.
    Lunec, John
    Tweddle, Deborah A.
    CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1108 - 1118
  • [9] Alterations of P53-Rb pathway parameters P53, P14ARF, Mdm2, Rb, P16INK4 and cyclin D1 in malignant mesothelioma
    Brambilla, E
    Lantuejoul, S
    Sturm, N
    Claraz, C
    Brichon, PY
    Galateau, F
    Brambilla, C
    LABORATORY INVESTIGATION, 2002, 82 (01) : 316A - 316A
  • [10] Alterations of P53-Rb pathway parameters P53, P14ARF, Mdm2, Rb, P16INK4 and cyclin D1 in malignant mesothelioma
    Brambilla, E
    Lantuejoul, S
    Sturm, N
    Claraz, C
    Brichon, PY
    Galateau, F
    Brambilla, C
    MODERN PATHOLOGY, 2002, 15 (01) : 316A - 316A